Novo Nordisk's pricing tactics while in the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who has accused the company of cost gouging, mentioning the stark distinction in between U.S. charges and people in Europe and copyright. Reports of Rybelsus and copyright have